Findings
Product development firms are hesitant to increase DHT use despite regulatory support.
Conventional hardware-based technologies are preferred over newer digital tools.
Operational barriers contribute to the low adoption of DHTs in product development trials.

Recommendations
Reduce operational barriers to facilitate DHT adoption.
Provide additional regulatory clarity to encourage DHT use.
Encourage the incorporation of more DHTs and patient-centric endpoints in clinical trials.

Regulatory Considerations
The FDA’s guidance on DHT use is evolving and not yet fully formalized.
There is a need for harmonization between US and non-US regulatory agencies.
The impact of recent regulatory support may take years to be fully realized.